Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus docetaxel versus docetaxel as second-line treatment after prior adebrelimab in extensive-stage small cell lung cancer
ChiCTR2400085196Phase 4Not yet recruiting
- Sponsor
- Deyang People's Hospital
- Start
- Jun 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of adebrelimab, docetaxel in small cell lung cancer (SCLC), sponsored by Deyang People's Hospital. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebrelimabdocetaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400085196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085196.